Q2 2022 Earnings Forecast for Athenex, Inc. (NASDAQ:ATNX) Issued By SVB Leerink

Athenex, Inc. (NASDAQ:ATNXGet Rating) – Stock analysts at SVB Leerink dropped their Q2 2022 EPS estimates for shares of Athenex in a research note issued on Tuesday, May 10th. SVB Leerink analyst J. Chang now forecasts that the company will post earnings per share of ($0.13) for the quarter, down from their prior estimate of ($0.08). SVB Leerink has a “Market Perform” rating and a $3.00 price target on the stock. SVB Leerink also issued estimates for Athenex’s Q3 2022 earnings at ($0.04) EPS, Q4 2022 earnings at ($0.02) EPS and FY2023 earnings at ($0.33) EPS.

Separately, Zacks Investment Research downgraded shares of Athenex from a “buy” rating to a “hold” rating in a report on Friday, April 15th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, Athenex has an average rating of “Hold” and an average target price of $3.00.

Shares of NASDAQ ATNX opened at $0.47 on Friday. The company has a 50 day simple moving average of $0.74 and a 200-day simple moving average of $1.20. The company has a market capitalization of $52.95 million, a P/E ratio of -0.27 and a beta of 0.98. The company has a debt-to-equity ratio of 3.00, a current ratio of 1.39 and a quick ratio of 1.03. Athenex has a 1 year low of $0.43 and a 1 year high of $5.27.

Athenex (NASDAQ:ATNXGet Rating) last released its earnings results on Tuesday, May 10th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. Athenex had a negative net margin of 176.47% and a negative return on equity of 113.34%. During the same period last year, the business posted ($0.27) EPS.

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in Athenex by 0.6% in the 4th quarter. BlackRock Inc. now owns 6,983,979 shares of the company’s stock valued at $9,500,000 after purchasing an additional 44,588 shares during the last quarter. Millennium Management LLC increased its holdings in Athenex by 28.4% in the 3rd quarter. Millennium Management LLC now owns 2,131,690 shares of the company’s stock valued at $6,416,000 after purchasing an additional 471,361 shares during the last quarter. Morgan Stanley increased its holdings in Athenex by 3,999.5% in the 2nd quarter. Morgan Stanley now owns 2,098,555 shares of the company’s stock valued at $9,696,000 after purchasing an additional 2,047,365 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Athenex by 34.1% in the 1st quarter. Renaissance Technologies LLC now owns 1,222,239 shares of the company’s stock valued at $1,014,000 after purchasing an additional 310,539 shares during the last quarter. Finally, Credit Suisse AG increased its holdings in Athenex by 39.7% in the 3rd quarter. Credit Suisse AG now owns 880,270 shares of the company’s stock valued at $2,650,000 after purchasing an additional 250,226 shares during the last quarter. Hedge funds and other institutional investors own 40.87% of the company’s stock.

About Athenex (Get Rating)

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies.

Further Reading

Earnings History and Estimates for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.